Sichuan Haisco Pharmaceutical

Executive Summary

Sichuan Haisco Pharmaceutical is a publicly traded, integrated Chinese pharmaceutical company with a focus on the research, development, and commercialization of small molecule and biologic therapies in central nervous system (CNS), oncology, and autoimmune diseases. Founded in 1999 and headquartered in Chengdu, the company has built a diversified portfolio leveraging expertise in both chemical drugs and biologics. Haisco has transitioned from a traditional pharma to an innovation-driven player, with multiple products on the market and a robust pipeline in clinical stages. The company's strategy centers on addressing high unmet medical needs in China and expanding into global markets, particularly through novel drug candidates and biosimilars. Financially, Haisco benefits from stable revenue from its commercial products, which supports ongoing R&D investments. Given its established manufacturing capabilities and regulatory experience, the company is well-positioned to navigate China's evolving healthcare landscape and capitalize on policy incentives for innovative drugs. Key near-term value drivers include progress in pivotal clinical trials, potential regulatory approvals, and strategic partnerships that could enhance its pipeline and market access. With a moderate conviction score, the company presents a balanced risk-reward profile, meriting attention from investors interested in China's biopharma sector.

Upcoming Catalysts (preview)

• Q4 2026NDA Submission for HS-10296 (CNS candidate) with NMPA75% success
• Q2 2026Phase III Top-line Results for HS-20094 (Oncology) in first-line lung cancer60% success
• Q3 2026Licensing Deal for HS-10234 (Autoimmune) with a global partner50% success